See more : Aquila European Renewables Income PLC (AERS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kiromic BioPharma, Inc. (KRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kiromic BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- APT PACKAGING LTD. (APTPACK.BO) Income Statement Analysis – Financial Results
- Shaanxi Energy Investment (001286.SZ) Income Statement Analysis – Financial Results
- Dr. Hönle AG (HNL.DE) Income Statement Analysis – Financial Results
- Aaron Industries Limited (AARON.NS) Income Statement Analysis – Financial Results
- Gushengtang Holdings Limited (2273.HK) Income Statement Analysis – Financial Results
Kiromic BioPharma, Inc. (KRBP)
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| Gross Profit | -2.80M | -2.07M | -469.80K | -200.00K | -87.50K | -80.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.62M | 13.92M | 11.37M | 5.05M | 1.20M | 1.42M |
| General & Administrative | 10.31M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Selling & Marketing | -2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.52M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Other Expenses | 0.00 | 0.00 | 53.40K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.14M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Cost & Expenses | 19.94M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.85M | 166.50K | 12.20K | 3.30K | 22.50K | 633.10K |
| Depreciation & Amortization | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| EBITDA | -16.30M | -32.50M | -25.74M | -19.00M | -3.62M | -3.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.94M | -31.11M | -25.74M | -19.20M | -3.71M | -3.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.01M | -3.62M | 147.00K | -3.30K | -22.50K | -633.10K |
| Income Before Tax | -20.95M | -34.73M | -25.59M | -19.20M | -3.73M | -3.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.45M | 65.60K | 3.30K | 22.50K | -80.24K |
| Net Income | -21.29M | -38.18M | -25.65M | -19.20M | -3.75M | -3.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| EPS Diluted | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| Weighted Avg Shares Out | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
| Weighted Avg Shares Out (Dil) | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
Top Penny Stocks To Buy Today? 3 To Watch Under $3
Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?
Why Kiromic Biopharma Shares Are Skyrocketing Today
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
4 Top Penny Stocks To Buy For Under $1 This Week
KRBP Stock: Why The Price Surged
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers
Kiromic BioPharma Announces Chief Financial Officer Transition
Source: https://incomestatements.info
Category: Stock Reports